A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • End date
    Mar 15, 2024
  • participants needed
  • sponsor
    Shanghai Henlius Biotech
Updated on 13 May 2022
measurable disease
lung cancer
administration intravenous


This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed). Part 2 is a randomized, open-label study, which will evaluate the safety and efficacy of HLX10 in combination with carboplatin+pemetrexed with or without HLX04(biosimilar of avastin) compared with treatment with carboplatin+pemetrexed in 1st line Stage IIIB/IIIC or IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (HLX10+HLX04+Carboplatin+Pemetrexed), Arm B (HLX10+HLX04 placebo+Carboplatin+Pemetrexed), or Arm C (HLX10 placebo + HLX04 placebo+Carboplatin+Pemetrexed).

Condition Carcinoma, Non-Small-Cell Lung
Treatment carboplatin, Pemetrexed, HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar
Clinical Study IdentifierNCT03952403
SponsorShanghai Henlius Biotech
Last Modified on13 May 2022


Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed, Stage IIIB/IIIC or IV non-squamous NSCLC
Participants with no EGFR, ALK and ROS1 mutation
Participants with no prior treatment for Stage IIIB/IIIC or IV non-squamous NSCLC
Measurable disease as defined by RECIST v1.1
Eastern Cooperative Oncology Group performance status 0 or 1
Adequate hematologic and end organ function

Exclusion Criteria

Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Active central nervous system metastases
Prior treatment with cluster of differentiation immune checkpoint blockade therapies or Bevacizumab
Has received a surgical operation within 4 weeks from the initial drug administration
Active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll
Currently having or have had interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity
Any active infection requiring systemic anti-infective therapy within 14 days prior to study drug administration
Uncontrollable active infection(s)
History of immunodeficiency, including HIV antibody positive
active hepatitis B; or hepatitis C virus infections
Has bleeding tendency
History of severe cardiovascular diseases
Known gastrointestinal diseases as follows, Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or > moderate esophageal varices
Pregnant or breastfeeding female
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note